natgillin/translations-raw huggingface dataset:
The pharmaceutically acceptable transdermal composition of claim 1, wherein the fatty alcohol is octanol, the terpene is limonene, and the composition further comprises tartaric acid. 
Farmaceutski prihvatljiv transdermalni sastav iz zahtjeva 1, naznačeno time da je masni alkohol okranol, terpen je limonen, te sastav dalje sadrži vinsku kiselinu.
A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient. 
Farmaceutski sastav, naznačen time, da obuhvaća spoj prema bilo kojem od prethodnih zahtjeva ili njegovu farmaceutski prihvatljivu sol, te farmaceutski prihvatljiv nosač ili prihvatljivo pomoćno sredstvo.
separating the solvent layers; and 
(ili) odvajanja slojeva otapala; i
the play objects within the recesses are articles that can be worn by the toy figure. 
igraći objekti (30, 50, 66, 76, 86, 96) u udubljenjima su artikli koje može nositi igraći lik.
Adjuster mandrel 47 includes a cylindrical portion 48 received within hollow housing 11 in the region below compression spring 24; and an external portion 49 that is engageable, e.g. by hand or by the application of a tool, from outside the hollow housing 11 via a side thereof. 
Podešivač 47 vretena sadrži cilindrični dio 48, prihvaćen u šupljem kućištu 11 u području ispod kompresijske opruge 24, 1 vanjski dio 49 koji je zahvaćen, ili ručno ili primjenom alata, s vanjske strane kućišta 11 s bočne strane.
a second light chain (LC2) comprising a light chain variable region 2 (VL2), wherein the VH1 and the VL1 pair to form a first antigen-binding site that specifically binds EGFR, the VH2 and the VL2 pair to form a second antigen-binding site that specifically binds c-Met, the HC1 comprises at least one substitution in the HC1 CH3 and the HC2 comprises at least one substitution in the HC2 CH3, and the substitution in the HC1 CH3 and the substitution in the HC2 CH3 occur at different amino acid residue positions, when residue numbering is according to the EU index, wherein: 
drugi laki lanac (LC2) koji sadrži varijabilnu regiju 2 lakog lanca (VL2), pri čemu se VH1 i VL1 spajaju da tvore prvo mjesto za vezanje antigena koje specifično veže EGFR, VH2 i VL2 se spajaju da tvore drugo mjesto za vezanje antigena koje specifično veže c-Met, HC1 sadrži najmanje jednu zamjenu u HC1 CH3 i HC2 sadrži najmanje jednu zamjenu u HC2 CH3, i zamjenu u HC1 CH3 i zamjenu u HC2 CH3 koja se pojavljuje na različitim položajima ostatka aminokiselina, kada je numeriranje ostataka u skladu sa EU indeksom, pri čemu VH1, VL1, VH2 i VL2 redom sadrže sekvence aminokiselina SEQ ID NOs: 189, 190, 193 i 194.
The vaccine kit of claim 23 wherein the first container further comprises hepatitis B surface antigen adsorbed on aluminium phosphate. 
Cjepivni komplet u skladu s patentnim zahtjevom 23, naznačen time što prvi spremnik dodatno sadrži površinski antigen virusa hepatitisa B, adsorbiran na aluminijev fosfat.
selective reduction of the ester function of methyl 5-(2-bromobenzamido)-1H-pyrrolo[2,3-b]pyridine-2-carboxylate by lithium aluminium hydride at room temperature, 
selektivna redukcija esterske funkcijske skupine metil-5-(2-bromobenzamido)-1H-pirolo[2,3-b]piridin-2-karboksilata litijevim aluminijevim hidridom pri sobnoj temperaturi,
In certain applications of the method, a plurality of cells from the mammal is provided with the rAAV vector ex vivo or in vitro, with the method further including an additional step of subsequently introducing the plurality of provided cells into at least a first tissue site within or about the body of the mammal. For example, the plurality of obtained cells may be introduced into at least a first site within one or both eyes of the mammal, including for example, by direct injection into the retina, the sub-retinal space, or to one or more tissues surrounding the retina, or to the entire eye, or to tissues surrounding the eye. 
Vektor ili pripravak za uporabu prema zahtjevima 15 ili 16, naznačen time što je mnoštvo stanica sisavca osigurano s rAAV vektorom ex vivo ili in vitro, te postupak nadalje obuhvaća uvođenje mnoštva osiguranih stanica barem u prvo mjesto tkiva unutar ili oko tijela sisavca ili gdje se mnoštvo dobivenih stanica unosi barem u prvo mjesto unutar jednog ili oba oka sisavca izravnom injekcijom u mrežnicu ili okolno tkivo.
This visit occurs at the end of the 14-week fixed-dose double-blind treatment period. 
ZOOM X. Razlika u odnosu na placebo na kraju tretmana za pacijente sa kohlearnim
a binding domain capable of binding to the mucin domain having seq ID:440, the three EGF-like domains having seq ID:441 or the Sushi/SCR/CCP domain having seq ID:442 of the extracellular domain of TEM1; and 
(d) vežuća domena, koja se može vezati na mucinsku domenu sa SEQ ID:440, tri EGF-u slične domene sa SEQ ID:441 ili Sushi/SCR/CCP domenu sa SEQ ID:442 izvanstanične domene TEM1; i
The resulting solution was then washed with water. 
Rezultirajuća otopina je tada isprana sa vodom.
wherein the apparatus is configured to fill the containers substantially simultaneously with a fluid. The apparatus of claim 1, wherein the first end of the housing has an outermost perimeter that is smaller in length than an outermost perimeter of second end. 
Uređaj u skladu s patentnim zahtjevom 1, naznačen time, da je vanjski opseg prvog kraja (A) kućišta (12) manji po duljini od vanjskog opsega drugog kraja (B) kućišta (12).
An aquaculture net (10) according to claim 9 or to claim 11, wherein said steel core (14) is a stainless steel. 
Mroža za akvakulturu (10) prema zahtjevu 9 ili zahtjevu 11, gdje je čelična jezgra (14) nehrđajući čelik.
A method according to claim 31 or claim 32, further comprising detecting target recognition by a cognate binder, and recovering cells of a clone containing DNA encoding the cognate binder. 
Postupak sukladno patentnom zahtjevu 31 ili patentnom zahtjevu 32, naznačen time, da dodatno obuhvaća detektiranje prepoznavanja ciljne strukture od strane srodnog vezujućeg sredstva, i rekuperiranje stanica klona koji sadrži DNA koja kodira srodno vezujuće sredstvo.
the subject taking an effective amount of a second colon cleansing solution,the second colon cleansing solution being a solution in water of: 
- drugu otopinu za čišćenje debelog crijeva, druga otopina za čišćenje debelog crijeva je otopina prema bilo kojem od zahtjeva 1 do 8.
The cap-locking member 107 may be an L-shaped ridge located at the lip of the container 106 . 
Dio za pričvršćivanje 107 može biti izbočenje u obliku slova L na rubu posude 106.
reacting Compound 12 with an alkyl haloformate to produce Compound 13: 
(b) reakcije Spoja 12 s alkil-halogenformijatom kako bi se dobilo Spoj 13:
The method of claim 9, wherein the white blood cells are selected from granulocytes, lymphocytes, monocytes and macrophages. 
Postupak prema zahtjevu 5, gdje su krvne stanice bijele krvne stanice.
the boost switch device comprises a first boost switch (Sb1) and a second boost switch (Sb2) are connected in series as a bidirectional switch between the first node (1) and the second node (2); and 
- < preklopni uređaj za pojačavanje sadrži prvo preklopno pojačalo (Sb1) i drugo preklopno pojačalo (Sb2) koja su serijski spojena kao dvosmjerni preklopnik između prvog čvora (1) i drugog čvora (2); te
The process of any one of claims 1-8 containing a further step of mixing the conjugate with further antigens optionally wherein the further antigens comprises at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 S.pneumoniae saccharides selected from the group consisting of 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F and 33F. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1-8, naznačen time što uključuje dodatni korak miješanja konjugata s dodatnim antigensom, gdje dodatni antigeni može uključivati u najmanju ruku 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 ili 20 S. pneumoniae saharide, koji se biraju iz skupine koju čine 1, 2, 3, 4,5, 6A, 6B, TF, 8, ON, 9V, 10A, IA, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F i 33F.
or a therapeutically acceptable salt thereof wherein R1, R2, and R3 are independently selected from the group consisting of hydrogen, alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkynyl, cyano, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, nitro, NRARB, and (NRARB)carbonyl; 
D, ili njegova terapijski prihvatljiva sol, naznačena time, da Ri, R> i Rs su neovisno odabrani iz skupine koja se sastoji od vodika, alkenila, alkoksi, alkoksikarbonil alkila, alkinila, cijano, haloalkoksi, haloalkila, halogena, hidroksi, hidroksialkila, nitro, NRARsg i (NRaRs)karbonila;
In a preferred embodiment, an 191P4D12 MAbs of the invention comprises heavy and light chain variable regions of an antibody designated Ha22-2(2,4)6.1 produced by a hybridoma deposited under the American Type Culture Collection (ATCC) Accession No.: PTA-11267 (See, FIG. 
Konjugat antitijela i lijeka prema patentnom zahtjevu 3, gdje antitijelo sadrži teški lanac koji se sastoji od sekvence amino kiseline teškog lanca antitijela proizvedenog hibridomom koje je pohranjeno u Američkoj kolekciji tipova kulture (ATCC) Acesijski Br.
In another embodiment, in formula (VII), R41 is selected from the group consisting of —H, methyl, ethyl, propyl, isopropyl, cyclopropyl, methoxy, ethoxy, propoxy, and cyclopropoxy. 
Spoj prema zahtjevu 19, pri čemu je R4, izabran iz skupine koju čine -H, metil, etil, propil, izopropil, ciklopropil, metoksi, etoksi, propoksi 1 ciklopropoksi.
Ω is as defined above; and p is 0 or 1. 
2 jest kao što je gore definirano, te p jest 0 ili 1.
A composition for use according to claim 1, comprising an amount of a MASP-3 inhibitory agent effective to increase the survival of red blood cells in a subject suffering from paroxysmal nocturnal hemoglobinuria (PNH). 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što sadrži količinu sredstva za inhibiranje MASP-3 koja djelotvorno povećava preživljenje eritrocita kod subjekta koji boluje od paroksizmalne noćne hemoglobinurije (PNH).
In one embodiment, the antibody or antibody fragment may bind human PD-1 with a kdissoc of about 2.7×10−5 1/s or slower. 
V/s ili sporije; veže se za humani PD-1 sa kggC od oko 2.7 x 10?
Optionally, a pressure control device or PCD (available commercially—see component 56 in dashed lines in FIG. 2) could be used to adjust the amount of air pressure from compressor 50 to conduit 14 . 
Po želji, može se koristiti regulator tlaka (PCD) (komercijalno dostupan - vidjeti komponentu 56 prikazanu isprekidanim linijama na slici 2) za podešavanje količine zraka pod tlakom od kompresora 50 do cjevovoda 14.
4-Cyano-3-propoxy-benzenesulfonyl chloride The titled compound was prepared analogously to 4-cyano-3-ethoxy-benzenesulfonyl chloride (Intermediate 127c) by replacing bromoethane with 1-bromopropane. 
4-cijano-3-propoksi-benzensulfonil klorid Naslovni spoj je prizveden analogno 4-cijano-3-etoksi-benzensulfonil kloridu (intermedijat 127c) zamjenom bromoetana s 1-brompropanom.
A compound which is (4-(4-[5-(6-trifluoromethyl-pyridin-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid, or a pharmaceutically acceptable salt thereof. 
Spoj, naznačen time, da je to (4Â«(4-[5-(6-trifluorometil-piridin-3-ilamino)-piridin-2-il]-fenil3-cikloheksil)-octena kiselina, ili njegova farmaceutski prihvatljiva sol.
Hydrolysis of Rapamycin Carbohydrate Derivatives in Human Whole Blood 
Hidroliza ugljikohidratnih derivata rapamicina u punoj ljudskoj krvi
According to a preferred embodiment of the present invention, in said stereoregular diblock polybutadiene, the 1,4-cis/1,2 molar ratio can range from 15:85 to 80:20, preferably ranging from 25:75 to 70:30. 
Stereoregularni diblok polibutadien u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se u navedenom stereoregularnom diblok polibutadienu molarni omjer 1,4-cis/1,2 kreće od 15:85 do 80:20.
Suitable sugars may be selected from the group of monosaccharides, disaccharides, and oligosaccharides, and typically from glucose, fructose, mannose, and sucrose. 
Pripravak iz patentnog zahtjeva 1, naznačeno time da pripravak nadalje sadrži sredstvo za podešavanje osmolalnosti odabranog iz skupine koju čine monosaharidi, disaharidi, oligosaharidi i polioli male molekulske mase.
A method for preparing an injection device suitable for intraepidermal and/or intradermally and/or subcutaneously, filled with a sterile and injectable composition, comprising at least the steps of: providing at least one gel of hyaluronic acid or a salt thereof in an injectable form, said hyaluronic acid being selected from a crosslinked hyaluronic acid form, a non-crosslinked hyaluronic acid form or a mixture thereof; 
Postupak za pripremu sterilnog i injektabilnog pripravka, naznačen time što postupak obuhvaća najmanje korake: a) osiguravanje najmanje jednog gela hijaluronske kiseline ili njezine soli, pri čemu je navedena hijaluronska kiselina odabrana od oblika umrežene hijaluronske kiseline, oblika ne- umrežene hijaluronske kiseline ili njihove smjese; b) dodavanje u navedeni gel hijaluronske kiseline barem mepivakain hidroklorida kao anestetičkog sredstva; i c) sterilizaciju smjese dobivene u koraku b).
In one embodiment in the pharmaceutical composition of the present invention, the at least one phosphate salt is a sodium phosphate, a potassium phosphate or an ammonium phosphate. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što je najmanje jedna fosfatna sol natrijev fosfat, kalijev fosfat ili amonijev fosfat.
Use according to claim 1, wherein the composition further comprises the peptides of SEQ ID NOS. 
Uporaba u skladu s patentnim zahtjevom 1, naznačena time, da pripravak nadalje sadrži peptide SEQ ID br.
A diagnostically effective amount of at least one anti-human CGRP antibody according to any one of claims 1 to 5 for use in a method of in vivo imaging that detects the presence of cells expressing CGRP comprising administering said at least one anti-human CGRP antibody, wherein said administration optionally further includes the administration of a radionuclide or fluorophore that facilitates detection of the antibody at CGRP expressing disease sites and wherein the results are optionally used to facilitate design of an appropriate therapeutic regimen. 
Dijagnostički djelotvorna količina najmanje jednog protutijela protiv ljudskog CGRP-a u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačena time što je namijenjena upotrebi u postupku vizualizacije in vivo kojom se detektira prisutnost stanica koje eksprimiraju CGRP koji se sastoji u primjeni navedenog najmanje jednog protutijela protiv ljudskog CGRP-a, gdje navedena primjena može dodatno uključivati primjenu radionuklida ili fluorofora koji olakšava detektiranje protutijela na bolesnim mjestima koja eksprimiraju CGRP 1 gdje se rezultate može upotrijebiti za olakšavanje osmišljavanja prikladnog režima terapije.
The hologram may be readable for an optical reader and thus form part of an information package comprised in the packaging. 
Hologram može biti čitljiv za optički čitač i na taj način može činiti dio informacijskog paketa koji je sadržan u pakiranju.
Treatment of connective tissue diseases of the skin 
Datum podnošenja europske prijave patenta:
According to another embodiment the carboxylic groups of the at least one carboxymethylcellulose are at least partly neutralized by adding to the aqueous mineral pigment material suspension prior or dining the grinding step d) one or more polyvalent cations, in situ formed, by adding an acid, preferably H3PO4, or acidic reacting salt, preferably CaHPO4. 
Postupak prema bilo kojem od zahtjeva 1 do 6, gdje su karboksilne skupine barem jedne karboksimetilceluloze barem djelomično neutralizirane tako da se vodenoj suspenziji mineralnog pigmentnog materijala dodaje prije ili za vrijeme koraka usitnjavanja d) jedan ili više polivalentnih kationa, in situ formiranih, putem dodavanja kiseline, poželjno H3POx, ili kiselo Teaktivne soli kao što je Na»HPOx, poželjno CaHPO1.
The residue was chromatographed on silica gel (10% methanol:dichloromethane) to give the title compound (0.33 g, 27%) as a yellow oil which was a mixture of diastereomers. 
Ostatak se kromatografira na silikagelu (10 % metanol/diklormetan) kako bi se dobilo naslovni spoj (0,33 g, 27 %) u obliku žutog ulja, koje je smjesa dijastereomera.
mixing the material from step a) with industrial by-products containing Fe(II) with an Fe concentration in the range 0.5 to 27.5% Fe (w/w); 
miješanje materijala iz koraka a) sa industrijskim sporednim proizvodima koji sadrže Fe(lIl) sa koncentracijom Fe u opsegu 0.5 do 27.5% Fe (m/m);
a group (a) which is —(CH2)s—NR8R9 wherein s is an integer ranging from 1 to 4 and R8 and R9 are independently hydrogen or (C1-C4) alkyl; and 
- skupina (a) koja je (CH2),-NReR, gdje je s cijeli broj u rasponu od 1 do 4 te Rz i Ry neovisno jesu vodik ili (Ci-C24) alkil; te
The antibody for use, conjugate for use or pharmaceutical composition for use of claim 34 or 35, wherein the method further comprises treating with a chemotherapeutic agent, radiation, or a cytokine. 
Antitijelo, konjugat ili farmaceutska kompozicija za uporabu prema patentnom zahtjevu 25 ili 26, pri čemu postupak dalje sadrži liječenje kemoterapeutskim sredstvom, zračenjem ili citokinom.
reacting an intermediate of formula (II) with R2b-B(OH)2 in the presence of a suitable catalyst, a suitable solvent, and a suitable base wherein W1 represents a suitable leaving group, wherein R2b represents Het or alkyl and wherein R1, R3 to R7, p, q and X are defined as in claim 1; 
reakciju intermedijera formule (II) sa R2b-B(OH)2 u prisutnosti pogodnog katalizatora, pogodnog otapala i pogodne baze [image] pri čemu W1 predstavlja pogodnu odlaznu skupinu, pri čemu R2b predstavlja Het ili alkil i pri čemu su R1, R3 do R7, p, q i X kako je definirano u patentnom zahtjevu 1;
A multi-armed polymer prodrug of claim 24, wherein said prodrug, when evaluated in a suitable animal model for solid tumor-type cancers and administered in a therapeutically effective amount, is effective to suppress tumor growth to an extent that is at least twice that observed for the unmodified anticancer agent when administered under the same conditions and at an equivalent dosage amount of anticancer agent over a time course of 30 days, based upon a comparison of tumor size. 
Višestruko razgranati polimerni prolijek iz patentnog zahtjeva 2, pri čemu je navedeni prolijek, procijenjen na odgovarajućem životinjskom modelu za karcinome čvrstog tipa 1 primijenjen u terapijski učinkovitoj količini, učinkovit za supresiju rasta tumora do razmjera koji je najmanje dvostruki od promatranog za nemodificirani agens protiv raka, koji je primijenjen na sličan način tijekom 30 dana.
The receiver of claim 7, wherein the first FEC decoder comprises: a de-puncturing means configured to perform de-puncturing on LDPC parity bits; an LDPC decoder configured to LDPC-decode the L1 signaling data and the de-punctured LDPC parity bits; and 
Prijamnik iz patentnog zahtjeva 7, pri čemu prvi FEC dekoder obuhvaća: sredstvo zatvaranja probijanja konfigurirano za zatvaranje probijanja na LDPC paritetnim bitovima;
This experiment is suitable for testing central muscle relaxant activity. 
Taj pokus je prikladan za ispitivanje djelovanja u smislu sredstva središnjeg djelovanja na relaksaciju mišića.
Filling said formwork with said cementitious mortar until said plurality of elements of transparent to light material appears completely buried in it without contacting with said mortar the opposite sides of said elements, suitable to form the inlet and the outlet of said opening, 
Punjenje okvira cementnim mortom sve dok više elemenata od materijala koji propušta svjetlost nije potpuno prekriveno mortom bez da mort dodiruje suprotne strane elemenata, prikladne za formiranje ulaza i izlaza otvora,
The immunoconjugate of any one of claims 1 to 4, wherein said Fc domain comprises one or more amino acid mutation that reduces the binding of the Fc domain to an Fc receptor, particularly an FcY receptor. 
Imunokonjugat iz bilo kojeg od patentnih zahtjeva 1 do 4, naznačen time, da navedena Fc domena obuhvaća jednu ili više mutacija aminokiselina, koja(e) smanjuje(u) vezanje Fc domene na Fc receptor, naročito Fey receptor.
The pharmaceutical compositions for separate administration of the combination partners and for the administration in a fixed combination, i.e., a single galenical composition comprising at least two combination partners, according to the invention can be prepared in a manner known per se and are those suitable for enteral, such as oral or rectal, and parenteral administration to mammals, including man, comprising a therapeutically effective amount of at least one pharmacologically active combination partner alone or in combination with one or more pharmaceutically acceptable carriers, especially suitable for enteral or parenteral application. 
Farmaceutski sastavi za odvojeno davanje kombinacije sudionika 1 za davanje u fiksnoj kombinaciji, tj. u obliku jednog galenskog sastava koji sadrži najmanje dva sudionika kombinacije prema izumu, mogu se pripraviti na način poznat kao takav 1 oni su prikladni za enteralno davanje, kao oralno ili rektalno, i parenteralno davanje sisavcima, uključiv čovjeku, a sadrže terapeutski učinkovitu količinu najmanje jednog farmakološki aktivnog sudionika kombinacije samog ili u kombinaciji s jednim ili više farmaccutski prihvatljivih nosača, posebno prikladnih za cnteralnu ili parcnteralnu primjenu.
The method according to claim 24, wherein said first and second shafts are formed as a common space. 
Postupak sukladno zahtjevu 10, pri čemu su navedeni prvi i drugi otvor formirani kao zajednički prostor.
The composition or vaccine for use according to any one of claims 1-9 or the vector for use according to claim 11, further wherein said composition, vaccine or vector is for use in a method of vaccinating an animal, the method comprising at least one administration of the composition, vaccine or vector. 
Pripravak ili cjepivo prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen/o time, da se upotrebljava u postupku induciranja zaštitne reakcije kod životinje, protiv NDV i opcionalno, protiv jednog ili više daljnjih ptičjih patogena, pri čemu taj postupak obuhvaća najmanje jednu primjenu pripravka ili cjepiva.
The mixture was cooled, quenched with 1N hydrochloric acid solution, and the mixture is extracted with ethyl acetate. 
Smjesa se hladi, polije s 1 N otopinom kloridne kiseline, i smjesa se ekstrahira etil-acetatom.
a polypeptide comprising an amino acid sequence having 80% or more identity to SEQ ID NO: 3 which can elicit an antibody that recognises SEQ ID NO: 3; or 
polipeptid koji sadrži aminokiselinsku sekvencu koja ima 80% ili više identičnosti sa SEQ ID NO: 10 koji može izazvati protutijelo koje prepoznaje SEQ ID NO: 10; ili
Method according to claim 1, in which the civil engineering structure comprises at least one stay cable array situated substantially in the same plane and including said pair of stay cables, and in which the damper is positioned so that an operating axis of said damper is substantially within said plane of the stay cable array. 
Postupak sukladno bilo kojem od prethodnih zahtjeva, pri čemu građevinska struktura (1) obuhvaća barem jedan niz kablova (4.5) smještenih u osnovi u istoj ravnini i uključujući navedeni par kablova, 1 pri čemu je amortizer (6) smješten na način da je operativna os amortizera u osnovi unutar ravnine niza kablova.
Sigma ligand for use according to claim 1, wherein the pain is selected from acute and/or chronic pain developed as a consequence of bone cancer, preferably neuropathic pain, neuralgia, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperpathia, neuritis or neuropathy secondary to surgical procedure. 
2. < Sigma ligand, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što se bol bira između akutne ifili kronične boli koja se pojavljuje kao posljedica raka kostiju, po mogućnosti neuropatske boli, neuralgije, alodionije, kauzalgije, hiperalgezije, hiperestezija, hiperpatije, neuritisa ili neuropatije kirurškog zahvata.